Phase Ib Study To Evaluate The Safety Of Combining IGF-1R Antagonist R1507 With Multiple Standard Chemotherapy Drug Treatments In Patients With Advanced Malignancies

Inclusion Criteria:

- adult patients, >=18 years of age;

- malignant neoplasms;

- failed prior standard curative therapy;

- ECOG performance Status of 0 or 1;

- adequate bone marrow, hepatic and renal function;

- life expectancy greater than 8 weeks.

Exclusion Criteria:

- chemotherapy within 2 weeks of start of therapy;

- prior irradiation within 4 weeks prior to start of therapy;

- prior treatment with agents targeting IGF-IR inhibition, or other investigational
agents;

- major surgery or significant traumatic injury within 2 weeks prior to study start;

- patients receiving concurrent antibody or immunotherapy;

- other exclusion criteria are related to specific treatment regimens.